A small spot of blood after menopause can seem too minor to mention. Yet the amount does not decide whether it needs checking. Hormonal changes can affect vaginal tissue, and hormone replacement therapy can alter bleeding patterns, but neither explanation should be assumed. The NHS advice on postmenopausal bleeding is to see a GP even after a single small episode.
Postmenopausal bleeding means vaginal bleeding more than 12 months after periods stopped because of menopause, as defined in NICE’s referral guidance. This definition does not mean other unusual bleeding should be ignored: the NHS also advises assessment for bleeding after sex.
Hormonal change can explain bleeding, but cannot diagnose it
After menopause, thinning of the vaginal lining or womb lining can cause bleeding. Clinicians call this atrophy. Other possible explanations include cervical polyps, thickening of the womb lining called endometrial hyperplasia, and, less commonly, cancer. The NHS overview of causes makes clear that treatment depends on which explanation is found.
Dryness deserves attention in its own right. The NHS guidance on vaginal dryness describes how lower hormone levels around menopause can contribute to discomfort, soreness, and pain during sex. It also specifically advises a GP appointment for bleeding after sex or after menopause. Having a plausible hormonal explanation does not remove that advice.
This distinction matters when symptoms overlap. Someone may have dryness and notice bleeding at the same time; that is useful information for the consultation, rather than proof of the bleeding’s source. Symptom relief and investigation answer different questions. One asks how to make daily life more comfortable. The other asks why blood appeared.
What the cancer figures actually mean
In a 2018 systematic review in JAMA Internal Medicine, Megan Clarke and colleagues combined 129 studies. Among women with postmenopausal bleeding, the pooled proportion diagnosed with endometrial cancer was 9%, with a 95% confidence interval of 8–11%. Conversely, 91% of women with endometrial cancer had experienced postmenopausal bleeding.
Those figures describe different groups. They do not mean that nine in ten people who notice blood have cancer. Most participants with bleeding did not have endometrial cancer. The finding supports taking the symptom seriously without treating it as a diagnosis.
The estimate also varied across regions and according to hormone-therapy use in the included studies. This was a synthesis of observational research, not an individual risk calculator. It cannot tell a reader what a particular spot of blood means today. That depends on an assessment of their own circumstances. A population average offers perspective; it cannot replace the examination and investigations that establish a cause.
HRT changes the pattern clinicians need to interpret
Different HRT regimens have different expected bleeding patterns. With sequential combined HRT, withdrawal bleeding at the end of each progestogen course can be expected. Continuous combined HRT can cause irregular bleeding or spotting during its first four to six months. The NHS explanation of HRT side effects sets out this distinction.
NICE recommendation 1.8.4, amended in 2026, explains that vaginal bleeding is common in people with a uterus during the first six months of systemic HRT or within three months of changing its dose or preparation. Bleeding should be discussed at the three-month review. NICE advises prompt medical help for unscheduled vaginal bleeding beyond these timeframes.
The NHS advice also calls for GP contact if bleeding becomes heavier or appears after a period without bleeding. These timeframes describe common treatment effects; they cannot establish the cause of an individual’s bleeding or justify delaying care when the pattern is concerning.
For the appointment, a record of the preparation, when it was started or changed, and how the bleeding relates to the treatment cycle can help frame the discussion. The question is whether this is expected bleeding for that regimen and stage of treatment. An article cannot establish that remotely. Decisions about altering treatment belong with the prescribing clinician.
Assessment may involve a scan, a biopsy, or both
In the UK, NICE’s suspected-cancer referral guidance recommends a suspected cancer pathway referral for unexplained postmenopausal bleeding not attributable to HRT in people aged 55 and over. It says clinicians should consider this pathway below 55. The age threshold is a referral recommendation, not a reason for younger people to ignore bleeding.
The NHS description of investigations for womb cancer includes a transvaginal ultrasound, in which a probe is placed in the vagina, and sampling cells from the womb lining. A hysteroscopy uses a thin camera to look inside the womb; a biopsy may happen during it or separately. The tests offered depend on the symptoms.
A referral to investigate cancer means the possibility needs checking. It is not a statement that cancer has been found. Before leaving the appointment, it is reasonable to ask which test is proposed, what question it answers, how results will arrive, and whom to contact if the expected update does not come.
Pain relief and consent belong in the conversation
Investigating bleeding should include a discussion of what the procedure may feel like. The NHS information on hysteroscopy acknowledges that it can be very painful for some people. Describing it as merely a quick check can miss an important part of the experience.
The same guidance says people should receive information about pain relief and can discuss their concerns before the day. Previous painful vaginal examinations, or experiences of sexual violence that could make the procedure difficult, are reasons to discuss additional support in advance. There is no need to disclose more personal detail here than someone feels able to share with their care team.
Sedation or a general anaesthetic may be possible, although availability varies and referral elsewhere may be needed. During the procedure, someone can ask for it to stop. Asking about these options is part of informed consent. It does not undermine the reason for investigating the bleeding.
Hormone treatment requires its own safety assessment
A prescription for dryness and a plan to investigate bleeding should not be confused. NICE’s menopause guidance supports vaginal oestrogen for menopause-related genitourinary symptoms, with review and shared decisions about the preparation. It describes much lower systemic exposure than with systemic HRT. That evidence concerns symptom treatment; it does not establish why someone is bleeding.
Unexplained vaginal bleeding is also a condition to disclose before starting continuous combined HRT, according to the NHS suitability guidance. Previous hormone-sensitive cancers, blood clots, and certain liver conditions also require attention. A reassuring account of menopause treatment in general cannot settle an individual’s suitability.
For systemic oestrogen, the NHS menopause treatment overview explains the importance of progestogen protection when the womb is present. Adjusting a regimen therefore involves more than suppressing an inconvenient symptom. This is a discussion with the prescriber, rather than a reason to experiment with doses.
What this means in practice
- Arrange a GP appointment for bleeding after menopause, including one small episode. This follows NHS advice; a second episode is not required before asking for help.
- Bring a short record of the bleeding and your medicines. If taking HRT, include its name, cycle, and recent changes so the clinician can interpret the pattern.
- Ask the prescriber what bleeding is expected with your particular HRT and what changes should prompt earlier contact.
- Before a proposed hysteroscopy, ask about pain relief, support, and alternatives to an outpatient procedure where appropriate.
- Ask who will explain the results and what the follow-up plan is if bleeding persists or returns. Keep that plan with the appointment information.
What we don’t know
The research cannot assign a personal cancer probability from the colour or amount of bleeding described in an article. The pooled risk estimate above includes varied populations and historical clinical settings. It should not be presented as a precise forecast for every reader, particularly when HRT use differs.
Nor can general guidance determine which investigation or hormone adjustment someone needs. That uncertainty is exactly what the consultation is intended to resolve. This article explains the reasoning behind assessment; it cannot identify the cause of an individual’s bleeding.
Hormonal changes deserve thoughtful care. Unexpected bleeding deserves a clear explanation, with comfort, consent, and follow-up built into the process.
Photo: SHVETS production on Pexels. Posed photograph illustrating a healthcare consultation; the people pictured are not identified as having any medical condition.
